Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Current Assets (2023 - 2026)

Prelude Therapeutics' Current Assets history spans 4 years, with the latest figure at $84.6 million for Q1 2026.

  • On a quarterly basis, Current Assets fell 17.39% to $84.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $84.6 million, a 17.39% decrease, with the full-year FY2025 number at $105.7 million, down 22.23% from a year prior.
  • Current Assets hit $84.6 million in Q1 2026 for Prelude Therapeutics, down from $105.7 million in the prior quarter.
  • Over the last five years, Current Assets for PRLD hit a ceiling of $235.6 million in Q4 2023 and a floor of $58.3 million in Q3 2025.
  • Historically, Current Assets has averaged $134.4 million across 4 years, with a median of $120.8 million in 2024.
  • Biggest five-year swings in Current Assets: tumbled 62.7% in 2025 and later dropped 17.39% in 2026.
  • Tracing PRLD's Current Assets over 4 years: stood at $235.6 million in 2023, then plummeted by 42.32% to $135.9 million in 2024, then dropped by 22.23% to $105.7 million in 2025, then fell by 19.96% to $84.6 million in 2026.
  • Business Quant data shows Current Assets for PRLD at $84.6 million in Q1 2026, $105.7 million in Q4 2025, and $58.3 million in Q3 2025.